The Ameliorative Effect of Ashwagandha- Withania somnifera (L.) Dunal on park25 Induced Neurodegeneration in Drosophila melanogaster Parkinson’s Disease Model
Mamatha Nagamadhu Murthy, V. Chandana, H. D. Nisarga, Baragur Venkatanarayanasetty Shyamala
European Journal of Medicinal Plants · pp. 1–12 · Published 27 Jun 2023
10.9734/ejmp/2023/v34i61140Abstract
Ashwagandha - Withania somnifera (L.) Dunal is a perennial shrub belonging to the family Solanaceae. Ashwagandha has been used for over 3000 years in traditional Indian Ayurveda for treatment of various neurological, and stress disorders. The root of Ashwagandha (ASH) is regarded as a tonic, aphrodisiac, narcotic, diuretic, anthelmintic, astringent, thermogenic and stimulant. Ashwagandha with other herbal decoctions was recognized to treat Kampavatha (Parkinson’s Disease) since 18th century. With this wide array of ethnopharmacological relevance, Ashwagandha has been recognized as one of the prominent complementary and alternative medicine to treat many neurodegenerative diseases like Alzheimer’s (AD) and Parkinson’s disease (PD). There is a prominent increase in the cases of AD and PD all over the world and it demands the requirement of complementary and alternative herbal remedies with no/minimal side effects. Many genetic factors are responsible for the onset and progression of PD. Loss-of-function mutations in the parkin gene are a major cause of early onset of autosomal recessive juvenile parkinsonism (AR-JP). Drosophila park25 loss of function mutants exhibit significantly increased number of mitochondria-endoplasmic reticulum contacts and a significantly decreased number of dopaminergic neurons in the adult brain which is the main cause of PD condition. Several studies have demonstrated the ability of Ashwagandha in imparting neuroprotection, improved locomotory ability, memory and learning abilities. The challenge lies in scrutinizing the mechanism and the pathways involved in the neuroprotective properties of this well-known herb. Here in our study, we test the possible neuroprotective effect of Ashwagandha on park25 mutants of Drosophila using lifespan analysis and climbing disability as a disease marker. Parkinson’s mimicking flies were administered with aqueous extraction of Ashwagandha-root mixed with the fly food and subjected to negative geotaxis assay. We observed that there is a prominent increase in the climbing ability in park25 treated flies compared to its age-matched untreated flies. This is the first report showing that, aqueous extraction of Ashwagandha-root extract was able to ameliorate the disease phenotype in the park25 Drosophila Parkinson’s disease model.
Cited by 6
Naimi Sirjohn, Gaurav Sharma, Duni Chand · 3 Biotech · 2025
Manpreet Kaur, Mukta Gupta · South African Journal of Botany · 2025
Showing 2 of 6 known citations — external sources report more than can currently be individually listed.
Related research
- An Overview on the Aetiology and Treatment of Alzheimer's Disease — shares topic coverage
- Proposal and Point of View on Targeting α-synuclein for the Treatment of Parkinson's Disease — shares topic coverage
- Autophagy: A Critical Review of Cellular Homeostasis and Pathophysiology — shares topic coverage
- Natural Medicines Enhancing Neurite Growth in Central Nervous System Disorders: A Review — shares topic coverage
- Neuroprotective Properties of NMDA R1 Antagonist (Ketamine) in Cyanide Treated Neurons in vitro — shares topic coverage
Article metrics
Real usage data collected on this platform.
3
Page views
0
PDF downloads
0
Outbound clicks
6
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.